Stock Groups

Regeneron Pharma Earnings, Revenue Beat in Q3 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Regeneron Pharma Earnings, Income Beat in Q3

Investing.com – Regeneron Pharma (NASDAQ:) reported on Thursday third quarter that beat analysts’ forecasts and income that topped expectations.

Regeneron Pharma introduced earnings per share of $15.37 on income of $3.45B. Analysts polled by Investing.com anticipated EPS of $10.17 on income of $2.72B.

Regeneron Pharma shares are down 3% from the start of the 12 months, nonetheless down 5.03% from its 52 week excessive of $686.62 set on September 3. They’re under-performing the S&P 500 which is up 24.08% from the beginning of the 12 months.

Regeneron Pharma follows different main Healthcare sector earnings this month

Regeneron Pharma’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on income of $23.34B, in comparison with forecasts EPS of $2.35 on income of $23.64B.

Thermo Fisher Scientific had beat expectations on October 27 with third quarter EPS of $5.76 on income of $9.33B, in comparison with forecast for EPS of $4.68 on income of $8.38B.

Keep up-to-date on all the upcoming earnings studies by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media want to remind you that the info contained on this web site shouldn’t be essentially real-time nor correct. All CFDs (shares, indexes, futures) and Foreign exchange costs will not be offered by exchanges however somewhat by market makers, and so costs might not be correct and should differ from the precise market value, which means costs are indicative and never acceptable for buying and selling functions. Due to this fact Fusion Media doesn`t bear any accountability for any buying and selling losses you may incur because of utilizing this information.

Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or injury because of reliance on the data together with information, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding types attainable.



[ad_2]